Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress
July 21, 2017
Longeveron LLC is sponsoring a regenerative medicine symposium at the 2017 International Association of Gerontology and Geriatrics (IAGG) World Congress on July 25 in San Francisco
NEWS PROVIDED BY
July 21, 2017
Longeveron LLC is sponsoring a regenerative medicine symposium at the 2017 International Association of Gerontology and Geriatrics (IAGG) World Congress on July 25 in San Francisco.
The symposium, titled Regenerative Medicine Alternatives for Aging Conditions, will feature a global panel of physicians who are experts in stem cell therapy and geriatric conditions, such as Aging Frailty and Alzheimer’s disease. Longeveron’s Co-founder and Chief Science Officer, Joshua M. Hare, M.D., will lead the panel, which includes Jeremy D. Walston, M.D. of Johns Hopkins University School of Medicine, Bruno Vellas, M.D., Ph.D. of Toulouse University Hospital, France, and Hidenori Arai, M.D., Ph.D., of National Center for Geriatrics and Gerontology, Japan.
According to Suzanne Liv Page, Longeveron’s Chief Operating Officer, “We are honored to bring together this panel of international experts to share cutting-edge science, trial results and experiences from around the globe.”
The primary objective of the symposium is to educate participants about the use of regenerative medicine therapies to study and treat various aging-related conditions. The panel will also discuss current Longeveron sponsored clinical trials to treat Aging Frailty and Alzheimer’s disease, and the approval pathways in Japan, Europe and the U.S., including the 21st Century Cures Act.
Regenerative medicine therapy for aging-related conditions is emerging as one of the most promising and intensely investigated areas of clinical research and development. Longeveron is a leader in stem cell research for aging conditions. The symposium is open to all registered attendees of the IAGG World Congress. For more information on the symposium visit www.iagg2017.org/program/industry-supported-symposia
The IAGG 2017 World Congress is July 23-27, and is the world’s largest conference on aging, providing a unique forum for medical and scientific researchers, clinicians and industry professionals to address issues impacting today’s older population.
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
SOURCE Longeveron LLC